A recent study conducted by researchers in India and Qatar has uncovered significant insights regarding vitamin D supplementation. It was found that a daily dosage of 400 IU effectively addressed deficiency, while higher doses of 600–800 IU were more consistently linked to achieving sufficient levels. Remarkably, 65.4% of participants who received 800 IU daily managed to normalize their vitamin D levels by the 12th week of the study.
“In this context, serum 25(OH)D serves as a robust biochemical marker of vitamin D status, reflecting the cumulative effects of dietary intake and endogenous synthesis,” the researchers stated in Nutrients.
“Emerging perspectives in precision nutrition further emphasize the role of such biomarkers in guiding individualized nutritional strategies, where biochemical responses may provide a more accurate basis for intervention than intake estimates alone.”
While high-dose regimens demonstrate the ability to quickly normalize vitamin D levels, the study suggests that a gradual and sustained enhancement in vitamin D status can be achieved through nutritionally relevant daily doses.
Study Details
The double-blind, randomized controlled trial involved 108 non-pregnant, non-lactating Indian women aged 18–35 years who had vitamin D insufficiency or deficiency, as indicated by serum 25-hydroxyvitamin D concentrations.
Participants were randomly assigned to one of four groups, each receiving a daily dose of vitamin D3 in the form of a fortified chocolate wafer for 12 weeks: 0 IU, 400 IU, 600 IU, or 800 IU. Throughout the trial, the researchers collected data on various factors including anthropometrics, blood samples, sun exposure, and dietary intake, checked at baseline, as well as at weeks four and eight, and at the conclusion of the study. The supplemented wafer served as the primary source of vitamin D for the participants, as the intake of fortified foods was minimal.
Results indicated that serum 25(OH)D concentrations rose substantially over time in all supplemented groups, reflecting a dose-dependent response.
“By week 12, 65.4% of participants in the 800 IU group achieved vitamin D sufficiency (≥20 ng/mL), compared to 37.0% in the 600 IU group and 26.9% in the 400 IU group, while only 7.4% reached sufficiency in the placebo group,” the researchers reported.
They also noted that “even the 400 IU dose, which aligns with the Indian Estimated Average Requirement (EAR), resulted in significant improvements by week 4, with 23.1% of participants achieving vitamin D sufficiency.”
Though parathyroid hormone levels decreased over time, no significant differences were observed in markers for bone turnover. This finding aligns with previous research suggesting that vitamin D supplementation at nutritionally relevant doses, without concurrent calcium intake, generally has modest and inconsistent effects on bone turnover markers.
Limitations of the study included a focused demographic and the exclusion of physical activity, sun exposure, and dietary intake in the main analytical models. The researchers acknowledged that an extended study duration may better capture structural bone changes and longer-term adaptations of the skeleton.
Source: Nutrients; doi: 10.3390/nu18091476; “The Dose–Response Effects of Vitamin D3 on Serum 25-Hydroxyvitamin D Levels in Vitamin D-Deficient Young Indian Women: A Randomized Controlled Trial.” Authors: C. Halcyon Peris et al.
